Motivational Incentives for Enhanced Drug Abuse Recovery: Methadone Clinics. - 1

The purpose of this study is to test the utilization of incentive values (considerably lower than those typically used in research clinics) to motivate clients to attend treatment and initiate and sustain abstinence...

Date First Received: April 5, 2002

Last Updated: June 11, 2009

Verified by: National Institute on Drug Abuse (NIDA), July 2008

Clinical Trial Phase: Phase 3 | Start Date: April 2001

Overall Status: Completed

Estimated Enrollment: 390

Brief Summary

Official Title: “Motivational Incentives for Enhanced Drug Abuse Recovery: Methadone Clinics”

Condition Keyword(s):

Intervention(s):

The purpose of this study is to test the utilization of incentive values (considerably lower than those typically used in research clinics) to motivate clients to attend treatment and initiate and sustain abstinence.

Study Type: Interventional

Study Design: Treatment, Randomized

Study Primary Completion Date: February 2003

Detailed Clinical Trial Description

The purpose of the proposed research is to implement and systematically evaluate, in community treatment settings, motivational incentive procedures that have been well researched and have proven efficacious in a variety of treatment research clinics. The study will determine if motivational incentives along with standard care therapy is more effective than standard therapy alone for the treatment of patients using cocaine or methamphetamine and entering a substance abuse treatment program.

Intervention(s) in this Clinical Trial

  • Behavioral: Behavior Therapy

Outcome Measures for this Clinical Trial

Primary Measures

  • ASI
  • Opioid and cocaine use
  • AIDS risk behavior

Criteria for Participation in this Clinical Trial

Inclusion Criteria:

  • 1. Recent admission to an opioid substitution (methadone maintenance) CTP. Completed at least 4 weeks of maintenance at time of study entry
  • 2. Evidence of cocaine or methamphetamine use Minimum of one documented positive urine within 2 weeks of study entry. For those exiting a controlled environment, any stimulant use within two weeks of entering the controlled environment

Exclusion Criteria:

  • 1. Unable to give informed consent (fails simple consent quiz)
  • 2. Answers yes to question: Are you in recovery from gambling? That is, have you stopped gambling because of previous gambling problems?

Gender Eligibility for this Clinical Trial: Both

Minimum Age for this Clinical Trial: 18 Years

Maximum Age for this Clinical Trial: N/A

Are Healthy Volunteers Accepted for this Clinical Trial?: No

Clinical Trial Sponsor Information

Lead Sponsor: National Institute on Drug Abuse (NIDA)

Overall Clinical Trial Officials and Contacts

Maxine Stitzer, Ph.D. Principal Investigator Johns Hopkins University  

Additional Information

Information obtained from ClinicalTrials.gov on July 02, 2009

Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00033020

Study ID Number: NIDA-CTN-0007-1

ClinicalTrials.gov Identifier: NCT00033020

Health Authority: United States: Federal Government

Data Elements

Clinical Trials Authorship and Review

Clinical Trials content is provided directly by the U.S. National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of specific clinical trials information contains a unique identifier which can be used to find further details directly from the National Institutes of Health.